Hamburg Says Generic Drug Reviews Would Slow In Wake Of GOP-Backed Budget Cuts
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA commissioner predicts poor outlook for medical product review if agency loses appropriations in fiscal 2011 and 2012.
You may also be interested in...
FDA Could Face 13% Funding Cut Under House FY '12 Appropriations Bill
House Republicans' proposal to cut funding in the fiscal year 2012 Agriculture/FDA appropriations bill by 13% would cost FDA about $475 million if it applied across the board to both USDA and FDA.
FDA Could Face 13% Funding Cut Under House FY '12 Appropriations Bill
House Republicans' proposal to cut funding in the fiscal year 2012 Agriculture/FDA appropriations bill by 13% would cost FDA about $475 million if it applied across the board to both USDA and FDA.
Pharma Industry "Well Positioned" In Current Budget Debate, Avalere's Mendelson Suggests
Avalere Health's Dan Mendelson says pharma looks likely to avoid any hits in the budgets being debated for 2011 and 2012, but ideas that would chip away at profits could make a comeback after 2012 elections.